With Boz Medical: Sign an evaluation and licensing agreement with UMOJA BIOPHARMA.

According to the announcement of Po Pharma, the company's wholly-owned subsidiary Nona Bio has signed an evaluation and licensing agreement with UMOJA BIOPHARMA, aiming to combine Nona Bio's HCAb Harbour Mice and NonaCarFxTM platform with UMOJA BIOPHARMA's VivoVecTM platform to jointly advance the development of multiple in vivo CAR-T cell products. The agreement marks a further deepening of the strategic partnership established between the two parties in September 2024. Nona Bio will have the right to receive upfront payments, potential option payments, and milestone payments, while UMOJA BIOPHARMA will be responsible for the subsequent development and commercialization of the products.